Symptomatic myeloma
Showing 1 - 25 of 7,077
Biology and Genetics of Smouldering Myeloma
Recruiting
- Smouldering Myeloma
- +2 more
- No intervention
-
London, United KingdomUniversity College London Hospitals
Sep 15, 2021
Recurrent Plasma Cell Myeloma Trial in Jacksonville (Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide)
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Dexamethasone
- +4 more
-
Jacksonville, FloridaMayo Clinic in Florida
Jan 4, 2023
People With Multiple Myeloma in Portugal
Recruiting
- Relapse and/or Refractory Multiple Myeloma
-
Braga, Portugal
- +7 more
Jun 9, 2022
Bone Pain, Metastatic Malignant Tumor in the Bone, Plasma Cell Myeloma Trial in United States (Quality-of-Life Assessment,
Recruiting
- Bone Pain
- +2 more
- Quality-of-Life Assessment
- +2 more
-
Duarte, California
- +7 more
Feb 25, 2022
Smoldering Multiple Myeloma Trial in Spain (carfilzomib, Lenalidomide, Dexamethasone)
Active, not recruiting
- Smoldering Multiple Myeloma
- carfilzomib
- +3 more
-
Barcelona, Spain
- +15 more
Feb 15, 2021
Primary Systemic Amyloidosis, Light Chain Deposition Disease Trial in United States (drug, genetic, other, procedure)
Active, not recruiting
- Primary Systemic Amyloidosis
- Light Chain Deposition Disease
- bortezomib
- +6 more
-
Denver, Colorado
- +6 more
Aug 24, 2022
Biological Relapse in Patients With Multiple Myeloma
Terminated
- Multiple Myeloma
-
Zaragoza, Aragón, Spain
- +43 more
Sep 7, 2021
Multiple Myeloma Trial in Germany (Bendamustine, Bortezomib, Prednisone)
Completed
- Multiple Myeloma
- Bendamustine, Bortezomib, Prednisone
-
Mannheim, Ba-Wü, Germany
- +14 more
Oct 14, 2020
Multiple Myeloma Trial in United Kingdom (Autologous Stem Cell Transplant (ASCT), Consolidation with 4 cycles of CarCyDex)
Active, not recruiting
- Multiple Myeloma
- Autologous Stem Cell Transplant (ASCT)
- Consolidation with 4 cycles of CarCyDex
-
Romford, Essex, United Kingdom
- +19 more
May 4, 2021
Multiple Myeloma Symptomatic Relapse and/or Refractory Disease
Completed
- Multiple Myeloma
- No Intervention
-
Cadiz, Andalucia, Spain
- +29 more
Sep 14, 2020
Multiple Myeloma Trial in Austria, Germany, Israel (Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA], Placebo 1.7 ml
Active, not recruiting
- Multiple Myeloma
- Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
- Placebo 1.7 ml Subcutaneous Solution
-
Graz, Austria
- +9 more
Aug 24, 2022
Developing Myeloma in a High-Risk Screened Population (PROMISE)
Recruiting
- Multiple Myeloma
- Sample of Blood
-
Baltimore, Maryland
- +2 more
Mar 22, 2022
Multiple Myeloma and Plasma Cell Tumor Trial in Rochester (dexamethasone, lenalidomide)
Completed
- Multiple Myeloma and Plasma Cell Neoplasm
-
Rochester, MinnesotaMayo Clinic
Jan 9, 2020
Biomarker for Infection Risk in CLL and MM
Not yet recruiting
- Multiple Myeloma
- Chronic Lymphocytic Leukemia
- Screening
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
May 3, 2023
Multiple Myeloma, Myeloma-Associated Amyloidosis Trial in Saint Louis (Selinexor, Lenalidomide, Dexamethasone)
Not yet recruiting
- Multiple Myeloma
- Myeloma-Associated Amyloidosis
- Selinexor
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Apr 6, 2023
Multiple Myeloma Trial in Miami (Teclistamab, Talquetamab, Daratumumab SC)
Not yet recruiting
- Multiple Myeloma
- Teclistamab
- +2 more
-
Miami, FloridaUniversity of Miami
Oct 20, 2023
Multiple Myeloma Trial in Denmark, Estonia, Norway (Selinexor 20 MG Oral Tablet, Bortezomib Injection, Lenalidomide capsule)
Recruiting
- Multiple Myeloma
- Selinexor 20 MG Oral Tablet
- +3 more
-
Aalborg, Denmark
- +10 more
Apr 22, 2022
Multiple Myeloma Trial in Vitoria-Gasteiz (Bortezomib, Melphalan, Prednisone)
Terminated
- Multiple Myeloma
- Bortezomib
- +2 more
-
Vitoria-Gasteiz, Araba, SpainAraba of University Hospital
Jan 14, 2020
Multiple Myeloma Trial run by the National Cancer Institute (NCI) (Dexamethasone, Carfilzomib, Daratumumab)
Recruiting
- Multiple Myeloma
- Dexamethasone
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023